Patents by Inventor Hans-Jurgen E. Hess
Hans-Jurgen E. Hess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090099175Abstract: The present invention if directed to certain cinnoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.Type: ApplicationFiled: February 28, 2007Publication date: April 16, 2009Inventors: Mark P. Arrington, Allen T. Hopper, Richard D. Conticello, Truc M. Nguyen, Hans-Jurgen E. Hess, Carla Maria Gauss, Stephen A. Hitchcock
-
Patent number: 4404372Abstract: 15-Substituted-.omega.-pentanorprostaglandin C-1 tetrazoles, imides and sulfonimides.Their use as anti-secretory agents or as agents for the control of fertility.Type: GrantFiled: June 13, 1977Date of Patent: September 13, 1983Assignee: Pfizer Inc.Inventors: Michael R. Johnson, Thomas K. Schaaf, Hans-Jurgen E. Hess
-
Patent number: 4377581Abstract: 2,4-Diaminoquinazolines of the formula ##STR1## wherein Y.sup.1 is hydrogen or chloro, Y.sup.2 is OR, Y.sup.3 is hydrogen or OR such than when Y.sup.1 is hydrogen, Y.sup.3 is OR and when Y.sup.1 is chloro, Y.sup.3 is hydrogen or OR, and the pharmaceutically acceptable salts thereof; R represents an alkyl group having from one to three carbon atoms;taken separately, R.sup.1 and R.sup.2 are each hydrogen, alkyl having from one to five carbon atoms, cycloalkyl having from three to eight carbon atoms, alkenyl or alkynyl each having from three to five carbon atoms or hydroxy substituted alkyl having from two to five carbon atoms, when taken together with the nitrogen atom to which they are attached R.sup.1 and R.sup.2 form a substituted or unsubstituted heterocyclic group optionally containing an atom of oxygen, sulfur or a second atom of nitrogen as a ring member; their use as antihypertensive agents, pharmaceutical compositions containing them and intermediates for their production.Type: GrantFiled: April 10, 1981Date of Patent: March 22, 1983Assignee: Pfizer Inc.Inventors: Hans-Jurgen E. Hess, Jasjit S. Bindra, Praful K. Shah
-
Patent number: 4351940Abstract: 2,4-Diaminoquinazolines of the formula ##STR1## wherein Y.sup.1 is hydrogen or chloro, Y.sup.2 is OR, Y.sup.3 is hydrogen or OR such that when Y.sup.1 is hydrogen, Y.sup.3 is OR and when Y.sup.1 is chloro, Y.sup.3 is hydrogen or OR, and the pharmaceutically acceptable salts thereof; R represents an alkyl group having from one to three carbon atoms;taken separately, R.sup.1 and R.sup.2 are each hydrogen, alkyl having from one to five carbon atoms, cycloalkyl having from three to eight carbon atoms, alkenyl or alkynyl each having from three to five carbon atoms or hydroxy substituted alkyl having from two to five carbon atoms, when taken together with the nitrogen atom to which they are attached R.sup.1 and R.sup.2 form a substituted or unsubstituted heterocyclic group optionally containing an atom of oxygen, sulfur or a second atom of nitrogen as a ring member; their use as antihypertensive agents, pharmaceutical compositions containing them and intermediates for their production.Type: GrantFiled: April 13, 1981Date of Patent: September 28, 1982Assignee: Pfizer Inc.Inventors: Hans-Jurgen E. Hess, Jasjit S. Bindra, Praful K. Shah
-
Patent number: 4342868Abstract: 15-Substituted-.omega.-pentanorprostaglandin C-1 tetrazoles, imides and sulfonimides.Their use as anti-secretory agents or as agents for the control of fertility.Type: GrantFiled: April 1, 1981Date of Patent: August 3, 1982Assignee: Pfizer Inc.Inventors: Michael R. Johnson, Thomas K. Schaaf, Hans-Jurgen E. Hess
-
Patent number: 4287341Abstract: 2,4-Diaminoquinazolines of the formula ##STR1## wherein Y.sup.1 is hydrogen or chloro, Y.sup.2 is OR, Y.sup.3 is hydrogen or OR such that when Y.sup.1 is hydrogen, Y.sup.3 is OR and when Y.sup.1 is chloro, Y.sup.3 is hydrogen or OR, and the pharmaceutically acceptable salts thereof; R represents an alkyl group having from one to three carbon atoms;taken separately, R.sup.1 and R.sup.2 are each hydrogen, alkyl having from one to five carbon atoms, cycloalkyl having from three to eight carbon atoms, alkenyl or alkynyl each having from three to five carbon atoms or hydroxy substituted alkyl having from two to five carbon atoms, when taken together with the nitrogen atom to which they are attached R.sup.1 and R.sup.2 form a substituted or unsubstituted heterocyclic group optionally containing an atom of oxygen, sulfur or a second atom of nitrogen as a ring member; their use as antihypertensive agents, pharmaceutical compositions containing them and intermediates for their production.Type: GrantFiled: March 3, 1980Date of Patent: September 1, 1981Assignee: Pfizer Inc.Inventors: Hans-Jurgen E. Hess, Jasjit S. Bindra, Praful K. Shah
-
Patent number: 4283417Abstract: The invention discloses certain novel 13,14-dihydro-15-alkenyl prostaglandins and 13,14-dihydro-15-alkynyl prostaglandins and analogs of each as well as the novel intermediates employed in their preparation. The 9-oxo compounds of this novel series demonstrate selective bronchodilator activity, certain of these are also useful as antisecretory agents.Type: GrantFiled: October 18, 1979Date of Patent: August 11, 1981Assignee: Pfizer Inc.Inventors: James F. Eggler, Hans-Jurgen E. Hess
-
Patent number: 4268522Abstract: The invention discloses certain novel 13,14-dihydro-15-alkenyl prostaglandins and 13,14-dihydro-15-alkynyl prostaglandins and analogs of each as well as the novel intermediates employed in their preparation. The 9-oxo compounds of this novel series demonstrate selective bronchodilator activity, certain of these are also useful as antisecretory agents.Type: GrantFiled: October 18, 1979Date of Patent: May 19, 1981Assignee: Pfizer Inc.Inventors: James F. Eggler, Hans-Jurgen E. Hess
-
Patent number: 4243595Abstract: The 15 aryl substituted-.omega.-pentanorprostaglandins and various intermediates empolyed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.Type: GrantFiled: July 15, 1976Date of Patent: January 6, 1981Assignee: Pfizer Inc.Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
-
Patent number: 4169895Abstract: N-alkylsulfonyl, N-alkanoyl and N-benzoyl 16,16-dimethyl-17-oxaprostaglandin E.sub.2 and E.sub.1 carboxamides having antisecretory biological activity as well as intermediates for their synthesis are disclosed.Type: GrantFiled: September 2, 1977Date of Patent: October 2, 1979Assignee: Pfizer Inc.Inventors: Hans-Jurgen E. Hess, Michael R. Johnson
-
Patent number: 4154949Abstract: 11-DESOXY-15-SUBSTITUTED-.omega.-PENTANORPROSTAGLANDINS AND VARIOUS INTERMEDIATES EMPLOYED IN THEIR PREPARATION. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.Type: GrantFiled: January 31, 1977Date of Patent: May 15, 1979Assignee: Pfizer Inc.Inventors: Michael R. Johnson, Thomas K. Schaaf, Jasjit S. Bindra, Hans-Jurgen E. Hess, James F. Eggler
-
Patent number: 4152527Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.Type: GrantFiled: December 27, 1973Date of Patent: May 1, 1979Assignee: Pfizer Inc.Inventors: Hans-Jurgen E. Hess, Thomas K. Schaaf
-
Patent number: 4143051Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.Type: GrantFiled: November 23, 1977Date of Patent: March 6, 1979Assignee: Pfizer Inc.Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
-
Patent number: 4134981Abstract: Fused heterocyclic ring systems in which a quinoline or a pyridine component is "fused" to a pyrimidine having a 2-methyl, 2-ethyl, or 2-acetyl group and a 4-keto group, and to similar ring systems in which a quinoline, a naphthalene or a pyridine component is "fused" to a pyrimidine having a 2-carboxy group and a 4-keto group, derivatives, and pharmaceutically-acceptable cationic salts thereof, and their use as antiallergy agents, and intermediates therefor.Type: GrantFiled: October 27, 1977Date of Patent: January 16, 1979Assignee: Pfizer Inc.Inventors: Thomas H. Althuis, Leonard J. Czuba, Hans-Jurgen E. Hess, Saul B. Kadin
-
Patent number: 4120962Abstract: Fused heterocyclic ring systems in which a quinoline or a pyridine component is "fused" to a pyrimidine having a 2-methyl, 2-ethyl, or 2-acetyl group and a 4-keto group, and to similar ring systems in which a quinoline, a naphthalene or a pyridine component is "fused" to a pyrimidine having a 2-carboxy group and a 4-keto group, derivatives, and pharmaceutically-acceptable cationic salts thereof, and their use as antiallergy agents, and intermediates therefor.Type: GrantFiled: April 11, 1977Date of Patent: October 17, 1978Assignee: Pfizer Inc.Inventors: Thomas H. Althuis, Leonard J. Czuba, Hans-Jurgen E. Hess, Saul B. Kadin
-
Patent number: 4113766Abstract: .omega.-TRISNORPROSTAGLANDINS HAVING AT THE 17-POSITION TWO HYDROGEN ATOMS AND ONE SUBSTITUENT OF THE FORMULA:(CH.sub.2).sub.n --O--(CH.sub.2).sub.m CH.sub.3wherein n is an integer of from 0 to 1, m is an integer of from 0 to 4; and having at the 15-position one hydrogen substituent or alkyl substituent of from 1 to 3 carbon atoms. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.Type: GrantFiled: March 26, 1975Date of Patent: September 12, 1978Assignee: Pfizer Inc.Inventor: Hans-Jurgen E. Hess
-
Patent number: 4113723Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.Type: GrantFiled: November 23, 1977Date of Patent: September 12, 1978Assignee: Pfizer Inc.Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
-
Patent number: 4102894Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.Type: GrantFiled: July 15, 1976Date of Patent: July 25, 1978Assignee: Pfizer Inc.Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf
-
Patent number: 4094899Abstract: .omega.-TRISNORPROSTAGLANDINS HAVING AT THE 17-POSITION TWO HYDROGEN ATOMS AND ONE SUBSTITUENT OF THE FORMULA:(CH.sub.2).sub.n --O--(CH.sub.2).sub.m CH.sub.3wherein n is an integer of from 0 to 1, m is an integer of from 0 to 4; and having at the 15-position one hydrogen substituent or alkyl substituent of from 1 to 3 carbon atoms. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.Type: GrantFiled: April 30, 1973Date of Patent: June 13, 1978Assignee: Pfizer Inc.Inventor: Hans-Jurgen E. Hess
-
Patent number: 4080368Abstract: The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.Type: GrantFiled: April 21, 1977Date of Patent: March 21, 1978Assignee: Pfizer Inc.Inventors: Hans-Jurgen E. Hess, Michael R. Johnson, Jasjit S. Bindra, Thomas K. Schaaf